← Back to Clinical Trials
Recruiting NCT06342492

NCT06342492 Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06342492
Status Recruiting
Phase
Sponsor Kansas City Heart Rhythm Research Foundation
Condition Heart Failure With Reduced Ejection Fraction
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-11-07
Primary Completion 2024-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Coronary Sinus Lead Revision

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-11-07 with a primary completion date of 2024-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure.

Eligibility Criteria

Inclusion Criteria: * All patients older than 18 years of age * Patients with HFrEF that underwent BVP-CRT * Experienced CS lead failure, whether initial or recurrent, subsequently replaced with transthoracic epicardial lead placement or CSP * Underwent Medtronic, Boston Scientific, or Abbott lead placement Exclusion Criteria: * Patients younger than 18 years of age * Transthoracic epicardial lead placement or CSP performed as the initial approach or for other reasons than lead replacement * Those for which CRT no longer provides symptom relief or mortality benefit.

Contact & Investigator

Central Contact

Donita Atkins

✉ datkins@kchrf.com

📞 816-651-1969

Principal Investigator

Naga Venkata K. Pothineni

PRINCIPAL INVESTIGATOR

Kansas City Heart Rhythm Institute

Frequently Asked Questions

Who can join the NCT06342492 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure With Reduced Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06342492 currently recruiting?

Yes, NCT06342492 is actively recruiting participants. Contact the research team at datkins@kchrf.com for enrollment information.

Where is the NCT06342492 trial being conducted?

This trial is being conducted at Overland Park, United States.

Who is sponsoring the NCT06342492 clinical trial?

NCT06342492 is sponsored by Kansas City Heart Rhythm Research Foundation. The principal investigator is Naga Venkata K. Pothineni at Kansas City Heart Rhythm Institute. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology